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Abstract
Background The study objectives were to assess the prognos-
tic value of quantitative PET and to test whether combining
baseline metabolic tumour burden with early PET response
could improve predictive power in DLBCL.
Methods A total of 147 patients with DLBCL underwent FDG-
PET/CT scans before and after two cycles of RCHOP. Quantita-
tive parameters including metabolic tumour volume (MTV) and
total lesion glycolysis (TLG) were measured, as well as the per-
centage change in these parameters. Cox regression analysis was
used to test the relationship between progression-free survival
(PFS) and the study variables. Receiver operator characteristics
(ROC) analysis determined the optimal cut-off for quantitative
variables, and Kaplan–Meier survival analysis was performed.
Results The median follow-up was 3.8 years. As MTV and
TLG measures correlated strongly, only MTV measures were
used for multivariate analysis (MVA). Baseline MTV (MTV-0)
was the only statistically significant predictor of PFS on MVA.
The optimal cut-off for MTV-0 was 396 cm3. Amodel combing
MTV-0 and Deauville score (DS) separated the population into
three distinct prognostic groups: good (MTV-0<400; 5-year
PFS > 90 %), intermediate (MTV-0≥400+ DS1-3; 5-year PFS
58.5 %) and poor (MTV-0≥400+ DS4-5; 5-year PFS 29.7 %)
Conclusions MTV-0 is an important prognostic factor in
DLBCL. Combining MTV-0 and early PET/CT response im-
proves the predictive power of interim PET and defines a
poor-prognosis group in whom most of the events occur.
Keywords Positron emission tomography . Diffuse large
B-cell lymphoma .Metabolic tumour volume . Deauville
score . Response assessment
Introduction
The cure rate of diffuse large B-cell lymphoma (DLBCL) has
improved over the last two decades with the addition of ritux-
imab to CHOP chemotherapy (RCHOP) and improvements in
dose intensity and supportive care [1, 2]. Nonetheless, a pro-
portion of patients are not cured with RCHOP, either due to
primary refractory disease or later relapse following an initial
response. Salvage treatments after RCHOP are less effective
than after CHOP, probably because the increased cure rate
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with upfront treatment leaves a worse prognostic group for
salvage [3, 4]. Early identification of patients unlikely to be
cured with RCHOP is an important step towards testing alter-
native approaches in order to improve their chance of cure.
18 F-fluorodeoxyglucose (FDG) PET/CT performed early
during a course of chemotherapy (interim PET, iPET) shows
early response and has been found to be prognostic in Hodg-
kin lymphoma [5–9]. This has led to several clinical studies
testing response-adapted treatment algorithms. However in
DLBCL, iPET studies have shown conflicting results
[10–21]. Even in studies showing a significant difference be-
tween early complete metabolic response (CMR) and partial
metabolic response (PMR), the progression-free survival
(PFS) in the partial response group has remained too high,
around 50 % at 2–5 years, to consider early change of treat-
ment. More recent response criteria, e.g. Deauville score (DS)
and the reduction in the maximum SUV (ΔSUVmax), have
not increased the positive predictive value of iPET in DLBCL,
and there is a need to improve the current response criteria by
exploring additional parameters to improve the predictive
ability of interim PET.
In addition to early treatment response, baseline character-
istics of the lymphoma, including tumour burden, impact sig-
nificantly on outcome [22]. Quantitative imaging methods
using PET/CT to assess total tumour burden are under devel-
opment and may be more predictive than existing methods
[23]. We hypothesised that patients may achieve a good early
metabolic response but their chance of cure may be different
based on pre-treatment tumour burden. The objectives of this
study were to assess the prognostic value of quantitative PET
measurements, particularly metabolic tumour burden, and to
test whether combining measurements of metabolic tumour
burden at baseline with early PET response could improve
the prognostic ability of iPET in DLBCL.
Patients and methods
Study population
This is a retrospective study including 147 consecutive pa-
tients treated at Guy’s and St Thomas’ Hospital, London, be-
tween March 2005 and August 2012, according to a prospec-
tively agreed-upon departmental protocol. The study was ap-
proved by the hospital review committee, and all patients gave
written informed consent. The inclusion criteria were as fol-
lows: histologically proven DLBCL, treatment with RCHOP
chemotherapy, PET/CT scans before and after two cycles of
chemotherapy, and a minimum follow-up of 12 months. Ex-
clusion criteria were coexistent low-grade lymphoma, other
malignancy or active sarcoidosis, previous anthracycline che-
motherapy, and no assessable disease on baseline PET/CT.
Treatment protocol
All patients received standard-dose RCHOP chemotherapy
[1]. Figure 1 summarises the treatment algorithm. PET/CT
scan after two cycles (iPET2) was not used to change treat-
ment unless there was definite evidence of progression or lack
of response, taking into consideration all clinical and labora-
tory information. Patients with CMR continued to a total of
6 cycles of chemotherapy or 3–4 cycles followed by involved-
field radiotherapy in the case of stage I or II non-bulky dis-
ease. Patients with PMR after two cycles received two further
cycles of RCHOP followed by repeat PET/CTscan (iPET4). If
iPET4 showed CMR or further response with residual uptake
(PMR), treatment continued to six cycles. All patients had an
end-of-treatment scan (CT if there was CMR on iPET; PET/
CT if there was PMR on iPET). Consolidation radiotherapy
was administered according to departmental protocol and cli-
nician discretion.
In total, seven patients changed treatment due to progres-
sive disease while on RCHOP. Two patients progressed after
cycle 2: one patient with rising lactate dehydrogenase (LDH)
and no significant response on PET, and a second patient
showing progression of disease on PET. Both were changed
to salvage chemotherapy but progressed and died. Two other
patients progressed after three cycles: one with recurrence of
palpable bulky lymphadenopathy and another with cytologi-
cally proven CNS relapse. Both were changed to salvage che-
motherapy but progressed and died. Two patients progressed
after cycle 4, both with increased FDG uptake: one was suc-
cessfully salvaged with further chemotherapy and radiothera-
py, and one died of progressive disease following salvage
high-dose chemotherapy and stem cell transplant. Finally,
one patient progressed after cycle 5 with increasing disease
bulk on CT, which was biopsy-proven, and died following
salvage chemotherapy.
With regard to radiotherapy (RT), 50 patients had RT. In 35
patients, RT was planned treatment as part of a combined
treatment approach for stage I or II disease (relapse=1/35).
Of the 15 with stage III or IV disease who received RT, three
had stage III disease and received RT to a residual focus of
uptake (relapse=0/3), and 12 had stage IV disease and re-
ceived RT for the following reasons: site of bony disease
(two), contralateral testicular RT (one), residual activity on
PET-6 (four), initial bulk and DS 3 on PET-6 (two), initial
bulk and residual mass (one), clinician discretion (two) (re-
lapse=1/12).
PET/CT scanning
PET/CT scans were performed after a 6-h fast. Images were
acquired from skull base to upper thighs 90 minutes after
administration of 370 MBq of 18 F-FDG using DST or VCT
scanners (GE Healthcare, Waukesha, WI, USA). Baseline and
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interim scans were performed on the same scanner. Quality
control procedures to ensure accurate quantitation developed
for clinical trials have been previously described [24]. Paired
scans were displayed using a fixed SUV scale and colour
table, and were reviewed by an experienced nuclear medicine
physician (SFB), who was blinded to clinical outcome and
other baseline parameters such as the International Prognostic
Index (IPI). The Deauville score was allotted by comparing
the uptake in the residual lesion with the highest uptake, if
present, with the intensity of uptake in normal mediastinum
and liver. A score of 5 was given if the maximum SUV in the
tumour was ≥3 times greater than the maximum SUV in a
large region of normal liver.
In-house software developed by MP was used to automat-
ically segment tumour volumes with SUV ≥2.5. Volumes
were edited by SFB to remove physiological uptake, e.g. myo-
cardium adjacent to mediastinal nodal disease. All tumour
volumes were summed to calculate the total metabolic tumour
volume (MTV). Tumour lesion glycolysis (TLG) was calcu-
lated as MTV × mean SUV in the volume.
The following parameters were determined on the baseline
scan: SUVmax-0, MTV-0 and TLG-0. The following param-
eters were determined on the scan after two cycles: SUVmax-
2, MTV-2, TLG-2 and the Deauville score. Changes in these
parameters during treatment were also calculated: % change in
SUVmax (ΔSUVmax), % change in MTV (ΔMTV), %
change in TLG (ΔTLG).
Statistical analysis
The endpoint of the study was PFS, defined as the time from
diagnosis to the point of progression or death from any cause.
Patients still alive were censored at the date of last contact.
To determine which measures were predictive of PFS, uni-
variate Cox regression (CR) analysis was performed on all
quantitative parameters as well as IPI and Deauville score.
The IPI score was analysed according to the standard prog-
nostic groups: low risk (0–1), low intermediate (2), high
intermediate (3), and high (4–5). Continuous measures were
grouped into tertiles. Variables which were significantly asso-
ciated with PFS in univariate analysis were included in mul-
tivariate analysis in order to identify measures independently
predictive of PFS.
Receiver operator characteristics (ROC) analysis was per-
formed on continuous variables to determine optimal cut-off
values. The effect of individual parameters on PFS was stud-
ied with Kaplan–Meier (KM) survival analysis using dichot-
omous grouping based on ROC analysis. IPI scores were
grouped into 0–1 and 2–5, and DS scores into 1–3 (CMR)
and 4–5 (incomplete response). For ΔSUVmax, we used the
previously reported cut-off of 66 % [22, 28].
Based on these results, a prognostic model combining
baseline and response parameters was constructed on which
KM survival analysis was performed.
Statistical significance was considered at p<0.05. Data
were analysed using SPSS software (IBM Corp. Released
2011. IBM SPSS Statistics for Windows, Version 20.0.
Armonk, NY: IBM Corp.).
Results
The median follow-up for 147 patients was 3.8 years
(range 1.3–7.9 years). The clinical characteristics are
summarised in Table 1. The 5-year PFS and OS rates
for the whole group were 65.4 % and 73.7 %, respec-
tively. Table 2 shows the descriptive statistics for the
quantitative PET parameters.
Univariate CR analysis (Table 3) showed that the following
variables were statistically significant: IPI, MTV-0, TLG-0,
DS, MTV-2, TLG-2, SUVmax-2 and ΔSUVmax.
MTV and TLG measures correlated very strongly at both
baseline and after two cycles (Pearson’s correlation coeffi-
cient, r=0.916 and r=0.961, respectively), as tertile groups
were almost identical. Therefore, only MTV was included in
multivariate analysis (MVA). The MVA included IPI, DS,
MTV-0, MTV-2, SUVmax-2 and ΔSUVmax, and showed
that MTV-0 was the only independent statistically significant
measure.
ROC analysis (Fig. 2) showed that the optimal cut-off for
sensitivity and specificity for MTV-0 was 396 cm3 (sensitivity
0.88, specificity 0.62) and for TLG-0 was 4541 (sensitivity
0.76, specificity 0.63). The optimal cut-offs for MTV-2 and
TLG-2 were skewed towards very low values (1.8 and 5.6
respectively), reflecting the fact that most patients had signif-
icant reduction in FDG activity after two cycles of chemother-
apy. Similarly, the cut-offs for ΔMTV and ΔTLG were
99.76 % and 99.9 %. Therefore, only the cut-offs for MTV-0
and TLG-0 were considered clinically meaningful.
We also examined the relationship between the presence of
bulky disease (defined as maximum tumour dimension
Fig. 1 Treatment protocol. CMR = complete metabolic response
(defined as Deauville score 1–3). Partial response was defined as
Deauville score 4–5 with improvement compared to baseline. No
response/progression was defined as Deauville score 4–5 with no
improvement or progression compared to baseline
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(MTD) in any direction ≥10 cm as defined by ROC analysis,
data not shown) and MTV-0. Overall, 59 patients (40 %) had
bulky disease. As expected, the presence of bulky disease
correlated with high MTV-0 (parametric Pearson's correlation
coefficient, r=0.557, p<0.001). However, MTV-0 predicted
the outcome of patients better than MTD. Overall concor-
dance was 79 % (41 % had low bulk and low MTV-0, and
38 % had high bulk and high MTV-0). Thirty-one patients
(21 %) had discordance of bulk and MTV-0 classification.
Twenty-six patients (18 %) had low bulk but high MTV-0,
and their 5-year PFS was 45 %. Five patients (3 %) had high
bulk but lowMTV-0, and their 5-year PFS was 100% (Fig. 3).
KM survival analysis showed that the following variables
were associated with PFS: IPI (0–1 v 2–5: X2 = 14.17,
p<0.001), MTV-0 (<400 vs. >400: X2= 34.17, p<0.001),
TLG-0 (<4500 vs. >4500: X2=20.13, p<0.001), DS (1–3
vs. 4–5: X2 = 10.51, p = 0.001), MTV-2 (<1.8 vs. >1.8:
X2 = 11.32, p= 0.001), TLG-2 (<5.6 vs. >5.6: X2 = 10.36,
p = 0.001), SUVmax-2 (<3 vs. >3: X2 = 5.3, p = 0.021),
ΔMTV (>99.8 % vs. <99.8 %: X2=6.36, p=0.012), ΔTLG
(>99.9 % vs. <99.9 %: X2 = 7.43, p= 0.006), ΔSUVmax
(>66 % vs. <66 %: X2=13.68, p<0.001). Figure 4 shows
examples of KM PFS analysis.
For overall survival analysis, the corresponding values
were: IPI (0–1 vs. 2–5: X2=18.4, p<0.001), MTV-0 (<400
vs. >400: X2 =23.9, p<0.001), TLG-0 (<4500 vs. >4500:
X2=12.8, p<0.001), DS (1–3 vs. 4–5: X2=7.13, p=0.008),
MTV-2 (<1.8 vs. >1.8: X2=4.1, p=0.043), TLG-2 (<5.6 vs.
>5.6: X2=3.65, p=0.056), SUVmax-2 (<3 vs. >3: X2=2.79,
p=0.095),ΔMTV (>99.8% vs. <99.8 %: X2=3.06, p=0.08),
ΔTLG (>99.9 % vs. <99.9 %: X2 = 2.81, p = 0.094),
ΔSUVmax (>66 % vs. <66 %: X2=6.49, p=0.011).
To test the study hypothesis that a combination of baseline
metabolic tumour burden and response after two cycles can
improve the prognostic ability of iPET-2 in DLBCL, we con-
structed a prognostic model combining MTV-0—the only sta-
tistically significant baseline measure on MVA—and DS. The
aimwas to identify a groupwith sufficiently poor prognosis that
clinicians might consider changing treatment, and large enough
to include most of the population events. Patients were classi-
fied into four groups according to the two parameters: MTV-
0<400+DS 1–3 (46 patients, 31 %), MTV-0<400+DS 4–5
(20 patients, 14 %), MTV-0≥400+DS 1–3 (36 patients, 24 %)
and MTV-0≥400+DS 4–5 (45 patients, 31 %) (Fig. 5a).
This model showed that patients with high baseline tumour
burden (MTV-0≥ 400) and poor response (DS 4–5) had a
much worse prognosis than the remainder of the study popu-
lation with 5-year PFS 29.7%. Patients with lowMTV-0 had a
favourable prognosis regardless of the DS after two cycles (5-
year PFS 90.9 and 95.0 %), and patients with high MTV-0
who responded well according to DS had an intermediate
prognosis (5-year PFS 58.5 %). The worst prognosis group
included 31 % of the study population but 58 % of the total
events (29/50). Hazard ratios (compared to the group with low
MTV-0 and low DS) were 0.49 (low MTV-0+high DS, 95 %
CI 0.06-4.21), 4.7 (high MTV-0+ low DS, 95 % CI 1.7-13.0)
and 10.1 (high MTV-0+high DS, 95 % CI 3.9-26.2).
We examined other models—e.g. replacing MTV-0 with
TLG-0 or IPI, replacing DS with ΔSUVmax or adding other
parameters to MTV-0 and DS—but none was able to predict a
worse prognostic group, and the current model remained the
simplest and most predictive. The model combining MTV-0
and ΔSUVmax, for example, is shown in Fig. 5b. The worst
prognosis group included only 11 % of patients and 26 % of
the events.
Table 1 Patient characteristics
Patient characteristics n= 147 (%)
Sex Female 74
Male 73
Age Range 22–86
Median 57
≥60 years 71 (48 %)
Performance status
0–1 103 (70 %)
2–4 44 (30 %)
Raised LDH 93 (63 %)
Extra-nodal sites ≥ 2 73 (50 %)
Bulky disease (≥10 cm) 59 (40 %)
Stage I 17 (11 %)
II 29 (20 %)
III 16 (11 %)
IV 85 (58 %)
IPI 0/1 45 (31 %)
2 18 (12 %)
3 38 (26 %)
4/5 46 (31 %)
IPI = International Prognostic Index, LDH= lactate dehydrogenase
Table 2 Mean, median and range of quantitative PET parameters
Mean Median Min Max
MTV-0 (cm3) 990.14 595.12 1.50 7357.20
TLG-0 (cm3) 6815.91 4669.52 5.69 36,570.00
SUVmax-0 27.89 27.25 5.38 110.52
MTV-2 (cm3) 34.97 0.59 0.00 1608.70
TLG-2 (cm3) 213.45 1.64 0.00 13,135.00
SUVmax-2 2.05 2.73 0.00 10.34
ΔMTV (%) −95.81 −99.95 −100.00 −6.95
ΔTLG (%) −96.88 −99.98 −100.00 −31.71
ΔSUVmax (%) −69.03 −70.21 −100.00 41.39
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Discussion
The addition of rituximab to CHOP chemotherapy has im-
proved the outcome of first-line treatment for DLBCL [1, 2],
but salvage therapy for patients who are not cured with
RCHOP is less effective than that after CHOP [3, 4]. Early
identification of patients who are unlikely to be cured with
RCHOP is an important step to enable testing of alternative
approaches. Although early response assessment using iPET
has been established in Hodgkin lymphoma, its role remains
controversial in DLBCL due to conflicting results [10–21] and
the inability to detect a group with sufficiently poor prognosis
even with new response criteria such as DS or ΔSUVmax
[25]. For example, a recently published study using DS
showed a statistically significant difference between scores
1–3 and 4–5 (85 % vs. 72 % respectively, p=0.047), but the
Table 3 Cox regression analysis
LEVELS CASES
(n = 147)
UNIVARIATE MULTIVARIATE
HR 95 % CI for HR HR 95 % CI for HR
IPI groups (0,1) 45 1.00 1.00
2 18 4.23 1.34 13.34 2.95 0.82 10.60
3 38 4.74 1.73 12.98 2.30 0.74 7.21
(4,5) 46 5.49 2.07 14.53 2.98 0.98 9.08
TREND: χ2 = 12.39 P-value = .0004 χ2 = 2.78 P-value = .0955
DS 1 34 1.00 1.00
2 18 0.74 .234 2.321 0.21 0.04 1.09
3 30 0.49 .169 1.402 0.06 0.01 0.42
4 47 1.33 .621 2.844 0.09 0.01 0.62
5 18 3.86 1.725 8.640 0.23 0.03 1.88
TREND: χ2 = 7.61 P-value = .0058 χ2 = 0.95 P-value = .3303
SUVmax-0 Lower 49 1.00
Tertiles Middle 49 1.44 .74 2.79
Upper 49 0.86 .41 1.78
TREND: χ2 = 0.17 P-value = .6831
MTV-0 Lower 49 1.00 1.00
Tertiles Middle 49 3.77 1.49 9.51 2.73 .89 8.40
Upper 49 5.81 2.38 14.14 3.46 1.10 10.86
TREND: χ2 = 16.54 P-value = .0000 χ2 = 4.00 P-value = .0454
TLG-0 Lower 49 1.00
Tertiles Middle 49 2.96 1.24 7.10
Upper 49 4.90 2.11 11.38
TREND: χ2 = 14.95 P-value = .0001
SUVmax-2 Lower 49 1.00 1.00
Tertiles Middle 49 1.40 .65 2.99 2.56 .20 33.22
Upper 49 2.46 1.22 4.96 0.98 .06 16.10
TREND: χ2 = 6.72 P-value = .0096 χ2 = 2.40 P-value = .1216
MTV-2 Lower 59 1.00 1.00
Tertiles Middle 39 1.49 .68 3.27 4.16 .49 35.29
Upper 49 3.09 1.58 6.05 8.08 .72 90.67
TREND: χ2 = 11.21 P-value = .0008 χ2 = 3.02 P-value = .0820
TLG-2 Lower 59 1.00
Tertiles Middle 39 1.49 .68 3.27
Upper 49 3.09 1.58 6.05
TREND: χ2 = 11.21 P-value = .0008
ΔSUVmax Lower 49 1.00 1.00
Tertiles Middle 49 0.97 .46 2.07 1.04 .32 3.31
Upper 49 2.16 1.11 4.21 1.16 .32 4.17
TREND: χ2 = 5.42 P-value = .0199 χ2 = 0.09 P-value = .7701
ΔMTV Lower 59 1.00
Tertiles Middle 39 2.63 1.30 5.33
Upper 49 2.02 .99 4.12
TREND: χ2 = 3.83 P-value = .0502
ΔTLG Lower 59 1.00
Tertiles Middle 39 2.66 1.31 5.40
Upper 49 2.00 .98 4.07
TREND: χ2 = 3.71 P-value = .0542
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worse group still had excellent PFS [18]. Another study using
ΔSUVmax also showed a statistically significant difference
between the two groups, while the worse prognostic group
still had a high PFS [17].
In order to improve the predictive ability of PET, we
assessed the prognostic value of various quantitative PET
parameters, and found that the pre-treatment total meta-
bolic burden was the strongest predictor of PFS. MTV-0
and TLG-0 were the most predictive quantitative mea-
sures on univariate analysis and were superior to the
standard tools for assessing pre-treatment risk and early
response, namely the IPI and DS. As results using MTV
and TLG were almost identical, we included only MTV
parameters in MVA, which showed that MTV-0 remained
statistically significant while IPI and DS did not. These
results confirm previous studies showing the prognostic
value of baseline metabolic tumour burden [26–29]; how-
ever, this is the first study to show that pre-treatment total
metabolic burden is more prognostic than either early
response or IPI in DLBCL.
We also examined the relationship between the pres-
ence of bulky disease (as defined by anatomical size
criteria) and MTV-0. Bulk has traditionally been consid-
ered a poor prognostic factor, although the IPI did not
include bulky disease [22]. The prognostic value of bulk
was demonstrated in the rituximab era, and the optimal
cut-off appeared to be 10 cm (measuring the maximum
tumour dimension =MTD) in RCHOP-treated patients
[30]. Measuring MTD is technically easier and quicker
than measuring MTV, so we compared the two param-
eters to determine which was more predictive and
whether bulk expressed as MTD could predict the same
outcome while being easier to measure. Using MTD
cut-off of ≥10 cm, 59 patients (40 %) were found to
have bulky disease. As expected, the presence of bulky
disease correlated with high MTV-0; however, MTV-0
predicted the outcome of patients much better than
MTD. Overall, the two parameters agreed in 79 % of
patients, but in 21 % of patients who had discordance
of bulk and MTV-0 classification, MTV-0 correctly pre-
dicted the outcome regardless of the presence or ab-
sence of bulk. Twenty-six patients (18 %) had low bulk
but high MTV-0, and their 5-year PFS was 45 %, while
five patients (3 %) had high bulk but low MTV-0, and
their 5-year PFS was 100 %.
While baseline metabolic burden was a very strong
predictor in this population, the change in metabolic
burden was less predictive. The percentage reductions
in MTV and TLG after two cycles (ΔMTV and ΔTLG,
respectively) were borderline statistically significant on
univariate analysis. On ROC analysis, the optimal cut-
offs for ΔMTV and ΔTLG were skewed (99.76 % and
99.9 %, respectively), indicating that most of the popu-
lation had a significant reduction in metabolic volume
after two cycles of chemotherapy. Similarly, the optimal
cut-offs for MTV-2 and TLG-2 were skewed towards
very low values (1.8 and 5.6, respectively).
On the other hand, ROC analysis showed that the
optimal cut-off for sensitivity and specificity for MTV-
0 was 396 cm3 (rounded to 400) and for TLG-2
was 4541 cm3 (rounded to 4500). These were consid-
ered clinically meaningful and were included in further
analysis. Using these cut-offs, KM survival analysis
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separated the study population into two distinct prog-
nostic groups with statistically significant differences in
PFS.
Other studies have reported optimal cut-offs for MTV-0
ranging from 220 to 625 cm3 [26, 27, 29]. The optimal
cut-off value is dependent on the characteristics of the
study population and the methodology of MTV measure-
ment. Studies with populations with better prognosis (e.g.
earlier stage, less bulky disease and/or low IPI) resulted in
lower cut-offs and vice versa. Song et al. [26] studied
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only stage 2–3 patients without extra-nodal involvement
and few (4.1 %) with bulky disease (>5 cm), and reported
the optimal cut-off as 220 cm3. Sasanelli et al. [29] in-
cluded patients from eight institutions, most with stage 3–
4 (82 %), with bulky disease (>10 cm) in 36 % and two
or more extra-nodal sites in 32 %, and found an optimal
cut-off of 550 cm3. Our study was non-selective and in-
cluded consecutive patients from one institution with all
stages and presentations of disease, and so is likely more
representative of the general population of DLBCL in clin-
ical practice. Interestingly, the optimal cut-off in our study
was in the middle of the wide reported range. The other
factor affecting MTV-0 cut-off is the measurement method.
We applied the method used by Song et al. [26], defining
the MTV by SUVmax cut-off of 2.5, while Sasanelli [29]
and Casanovas [27] used a threshold of 41 % of SUVmax
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in each lesion to define MTV. Meignan et al. [31] recently
published a study evaluating different methods using phan-
tom and patient data, and concluded that 41 % is the
optimal cut-off to define MTV in lymphomas, in line with
solid tumours [32]. Our study, however, was conducted
before this recent publication. Validation studies comparing
the prognostic ability of the two methods are needed to
resolve this issue, but it seems that in the current study
population, the MTV-0 cut-off of 400 cm3, defined by
SUVmax>2.5, resulted in a clinically significant separa-
tion of low- and high-MTV-0 groups (3-year PFS 92.2 %
vs. 47.6 %) and compares favourably to MTV-0 defined
by 41 % of SUVmax (3-year PFS 77 % vs. 60 %) [29].
One of the study objectives was to test the hypothe-
sis that a combination of baseline measurement of met-
abolic tumour burden and early response assessment
could improve the prognostic ability of iPET-2 in
DLBCL. The model combining MTV-0 and DS was
able to separate significantly different prognostic groups
and to identify a group with a prognosis sufficiently
poor that clinicians might consider changing treatment.
Patients with high baseline tumour burden (MTV-
0≥ 400) and poor response after two cycles (DS 4–5)
had a much worse prognosis than the remainder of the
study population with 5-year PFS of 29.7 %. This com-
pares favourably with either DS alone (5-year PFS of
poor prognosis group 49.6 %) or ΔSUVmax alone (5-
year PFS of poor prognosis group 36.2 %, but this
group included only 16 % of patients). Patients with
low MTV-0 had a favourable prognosis regardless
of their DS after two cycles (5-year PFS 90.9 and
95.0 %), indicating that pre-treatment prognosis is more
important than early response in this group. Conversely,
patients with high MTV-0 who responded well accord-
ing to DS had an intermediate prognosis (5-year PFS
58.5 %). It is also worth noting that MTV-0 separated
the DS 4–5 patients into the best and the worst prog-
nostic groups, and correctly reclassified 20 patients
as good prognosis with 5-year PFS 95 %. Finally, the
worst prognosis group included 58 % of the total num-
ber of events (29/50) and 31 % of patients, making
this model useful for identifying patients with poor
prognosis.
Our results have significant clinical implications, and
the proposed prognostic model based on both initial
metabolic burden and response after two cycles of che-
motherapy could be used in both clinical practice and
future clinical trials. Most notably, the separation of
poor early responders (DS 4–5) into very different prog-
nostic groups (best and worst) depending on MTV-0 can
potentially be used to test response-adapted treatments.
However, the proposed model must be validated in
another independent data set to confirm its prognostic
value and optimal cut-off, and to test it against MTV
defined by 41 % cut-off.
The recently published imaging guidelines (ICML
guidelines) [23] and Lugano classification [33] now rec-
ommend performing PET/CT for staging in all FDG-
avid lymphomas, and baseline scan information should
be readily available. In addition, efforts to standardise
PET methods to ensure quantitative accuracy in every-
day practice [32, 34] and the increasing availability of
automated software from manufacturers to measure met-
abolic volumes make quantitative analysis in the clinic a
realistic option in the near future.
Conclusions
Baseline metabolic tumour volume is an important prog-
nostic factor in diffuse large B-cell lymphoma treated
with RCHOP chemotherapy. The combination of base-
line metabolic tumour volume and response on PET/CT
after two cycles measured by Deauville score improves
the predictive power of interim PET and separates pa-
tients into distinct groups with different prognosis, de-
fining a poor-prognosis group which includes most of
the events after treatment.
IPI, international prognostic index; DS, Deauville score
after 2 cycles; SUVmax-0, baseline maximum standardised
uptake value; MTV-0, baseline metabolic tumour volume;
TLG-0, baseline total lesion glycolysis; SUVmax-2, maxi-
mum standardised uptake value after 2 cycles; MTV-2,
metabolic tumour volume after 2 cycles; TLG-2, total le-
sion glycolysis after 2 cycles; ΔSUVmax, percentage
change in maximum standardised uptake value; ΔMTV,
percentage change in metabolic tumour volume; ΔTLG,
percentage change in total lesion glycolysis; ROC, receiver
operator characteristics
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